Phase 3 Clinical Trials With Primary Completion Dates in April 2017
This is a list of Phase 3 trials with primary completion dates in April 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ARGS||Argos Therapeutics, Inc.||2017-04-01||Phase 3||NCT01582672||Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma|
|BIVV||Bioverativ Inc.||2017-04-01||Phase 3||NCT02502149||Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale|
|CBPO||China Biologic Products, Inc.||2017-04-01||Phase 3||NCT01979900||Phase III Clinical Study of Efficacy and Safety of Vaccaeâ¢ to Prevent Tuberculosis|
|CEMP||Cempra, Inc.||2017-04-01||Phase 3||NCT02210325||Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea|
|CPHI||China Pharma Holdings, Inc.||2017-04-01||Phase 3||NCT01979900||Phase III Clinical Study of Efficacy and Safety of Vaccaeâ¢ to Prevent Tuberculosis|
|NOVN||Novan, Inc.||2017-04-01||Phase 3||NCT02672332||P3 Study in Acne Comparing Once Daily SB204 and Vehicle|
|NOVN||Novan, Inc.||2017-04-01||Phase 3||NCT02667444||P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne|
|VRX||Valeant Pharmaceuticals International, Inc.||2017-04-01||Phase 3||NCT02786901||LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|